国际癌症个体化创新医学组织（Worldwide Innovative Networking in personalized cancer medicine, WIN）是一家由美国MD Anderson 癌症中心和法国IGR （Institute Gustave Roussy）癌症中心及17家国际知名癌症中心共同发起的非盈利性机构。该机构的目标旨在通过癌症诊疗研究中心、医药研发和器械设备公司、政府机构及病人团体之间的合作，促进肿瘤遗传分子生物学标记物的重大基础研究成果向临床应用转化，力争在癌症的早期诊断和个体化靶向治疗领域取得突破性进展来攻克肿瘤。
现WIN向各成员单位征集研究和临床项目。请有意申报者于5月15日前将填好的项目申报表（见附件）发送至国际事务部
具体要求如下：
Directorate of WIN has decided to launch a new call for research projects among our members.
The project/trial proposals should be fully aligned with the mission of WIN, which is to achieve rapid and efficient translation of ground breaking early diagnostic and personalized cancer medicine discoveries into the standards for clinical care, to significantly improve the outcomes and quality of life of cancer patients.
WIN provides access to diverse populations of patients who vary in genetic and cultural backgrounds. This is important in evaluating new biomarker and targeted therapies.
Proposals can address one of the following categories, or others:
? Cancer Detection/Early Diagnosis
? Prognostic Biomarkers
? Predictive Biomarkers for treatment selection
? Biomarkers for monitoring Disease
? Targeted therapy alone and in combinations
? Data mining
The projects/trials will be primarily evaluated for their originality, innovation and potential clinical impact.
Remember that each project/trial is Principal Investigator-initiated and will be sponsored and administered by the Principal Investigator’s institution and/or the other institutions that are participating. The proposal should provide a plan for securing funding of the clinical trial and companion laboratory studies. The proposal must include a description of planned grant applications including agency or commercial sponsor, planned submission date, anticipated funding date if successful and estimated budget. WIN Consortium’s role will be to help in planning the trial and assist the Principle Investigator in raising funds.
Proposals will be submitted for evaluation to the WIN Scientific Advisory Board by end of May. The SAB will have a first meeting to discuss the proposals’ evaluations during the WIN Symposium in Paris on July 12.
The proposals should be submitted in electronic format (tables or schema may be converted to .pdf format to assure accurate transfer) using the attached form .
Each of the scientific sections should be sufficient to constitute the corresponding sections of a final protocol, but they should not be excessive or encyclopedic.